These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 22143533

  • 21. In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.
    Gracias S, El Yaalaoui I, Visseaux B, Charpentier C, Descamps D, Martin C, Lermechain F, Plantier J-C, Alessandri-Gradt E.
    Microbiol Spectr; 2024 Jul 02; 12(7):e0389523. PubMed ID: 38809042
    [Abstract] [Full Text] [Related]

  • 22. Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.
    Ruiz-Mateos E, González-Serna A, Genebat M, Machmach K, Vidal F, Muñoz-Fernández A, Ferrando-Martinez S, Leal M.
    Antimicrob Agents Chemother; 2011 Oct 02; 55(10):4664-9. PubMed ID: 21807977
    [Abstract] [Full Text] [Related]

  • 23. HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
    Recordon-Pinson P, Raymond S, Bellecave P, Marcelin AG, Soulie C, Descamps D, Calvez V, Harrigan PR, Fleury H, Izopet J, Masquelier B, S AC11 Resistance Study Group.
    Antimicrob Agents Chemother; 2013 Feb 02; 57(2):930-5. PubMed ID: 23208718
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM, Kanmogne GD.
    Drug Des Devel Ther; 2015 Feb 02; 9():5447-68. PubMed ID: 26491256
    [Abstract] [Full Text] [Related]

  • 33. Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
    van Lelyveld SF, Symons J, van Ham P, Connell BJ, Nijhuis M, Wensing AM, Hoepelman AI.
    Int J Antimicrob Agents; 2016 Jan 02; 47(1):84-90. PubMed ID: 26585497
    [Abstract] [Full Text] [Related]

  • 34. Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.
    Gonzalez-Serna A, Genebat M, De Luna-Romero M, Tarancon-Diez L, Dominguez-Molina B, Pacheco YM, Muñoz-Fernández MA, Leal M, Ruiz-Mateos E.
    Antimicrob Agents Chemother; 2016 Oct 02; 60(10):6398-401. PubMed ID: 27480849
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G, Watson DC.
    Crit Rev Microbiol; 2015 Oct 02; 41(4):473-87. PubMed ID: 24635642
    [Abstract] [Full Text] [Related]

  • 40. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
    Roche M, Jakobsen MR, Ellett A, Salimiseyedabad H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR.
    Retrovirology; 2011 Nov 07; 8():89. PubMed ID: 22054077
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.